```html

Kraurosis Vulvae (Atrophic Vulvar Lichen Sclerosus)

Overview

Kraurosis vulvae, also known as atrophic vulvar lichen sclerosus, is a chronic inflammatory skin condition that primarily affects the vulva. It leads to thinning, whitening, and tightening of the skin, which can cause pain, itching, and, in severe cases, scarring that narrows the vaginal opening.

• Population affected: Most commonly diagnosed in pre‑pubertal girls and post‑menopausal women, but it can occur at any age.
• Prevalence: Estimates range from 0.1 % to 0.3 % of the general female population, with higher rates (up to 5 %) reported among women who seek care for vulvar symptoms. Women with autoimmune disease have a 2‑3‑fold increased risk. CDC, Mayo Clinic.
• Why the name? “Kraurosis” is an older term describing the atrophic (shrunken) appearance of the vulvar skin; “lichen sclerosus” is the preferred modern terminology in most guidelines.

Symptoms

Symptoms can be mild and go unnoticed for years, or they may be severe enough to disrupt daily activities. The typical clinical picture includes:

Cutaneous signs

• White, parchment‑like plaques: Often described as “paper‑thin” or “cigarette‑paper” skin.
• Skin thinning and atrophy: The tissue becomes fragile and may tear easily.
• Fissures or cracks: Common at the introitus (vaginal opening) and labia minora.
• Loss of genital tissue (scar tissue): Can lead to “bridging” or fusion of labial tissue.

Symptoms reported by patients

• Intense itching (pruritus) – often the earliest symptom.
• Burning or stinging sensations, especially after sexual activity or tampon use.
• Dyspareunia (painful intercourse) due to tightening of the vaginal opening.
• Discomfort during urination (dysuria) or a feeling of incomplete emptying.
• Bleeding or spotting from fissures, especially after intercourse.
• Psychological distress – embarrassment, anxiety, or reduced sexual satisfaction.

Causes and Risk Factors

The exact cause of kraurosis vulvae is unknown, but research points to a multifactorial origin.

Potential etiologic factors

• Autoimmune mechanisms: Up to 30 % of women with lichen sclerosus have another autoimmune disease (e.g., thyroiditis, vitiligo, type 1 diabetes). Antibodies against extracellular matrix proteins have been detected in skin biopsies. NIH.
• Genetic predisposition: Familial clustering suggests a heritable component, though no single gene has been identified.
• Hormonal factors: Post‑menopausal estrogen deficiency may exacerbate skin thinning, though the disease can occur in pre‑pubertal girls, indicating hormones are not the sole driver.
• Infectious triggers: Some studies have linked prior viral infections (e.g., HPV, HSV) to an altered local immune response.
• Chronic irritation: Repeated friction from tight clothing, harsh soaps, or sexual activity may act as a secondary irritant, worsening existing disease.

Risk factors

• Female sex (the condition is almost exclusive to women).
• Age – peaks in early childhood and after age 50.
• Personal or family history of autoimmune disease.
• Previous vulvar surgery or trauma.
• Low socioeconomic status – associated with delayed diagnosis and less access to specialized care.

Diagnosis

Diagnosing kraurosis vulvae relies on a combination of clinical evaluation and, when needed, histopathology.

Clinical examination

• Visual inspection: A trained clinician looks for the characteristic white, atrophic plaques and any fissures or scarring.
• Palpation: Assessing the thickness of the skin and tenderness.
• Patient history: Duration of symptoms, prior treatments, and associated autoimmune conditions.

Biopsy

While many clinicians diagnose based on appearance alone, a skin punch biopsy is recommended when:

• The presentation is atypical.
• There is suspicion for malignancy (particularly vulvar squamous cell carcinoma, which has a 4‑5 % lifetime risk in untreated lichen sclerosus). Cleveland Clinic.

Histologic hallmarks include epidermal thinning, a band of homogenized collagen in the superficial dermis, and a lichenoid inflammatory infiltrate.

Additional tests

• Thyroid function tests or ANA panels if an associated autoimmune disease is suspected.
• HPV testing is generally not required unless there are co‑existing lesions suggestive of HPV infection.

Treatment Options

Effective management aims to control symptoms, halt disease progression, and prevent complications such as malignancy.

Topical corticosteroids (first‑line)

• Clobetasol propionate 0.05 % ointment: Applied once daily for 6–12 weeks, then tapered to a maintenance schedule (e.g., twice weekly). Studies report symptom relief in >80 % of patients. Mayo Clinic.
• Potential side effects: skin thinning, striae, or secondary infection—generally mild if used as directed.

Second‑line topical agents

• Calcineurin inhibitors (tacrolimus 0.1 % or pimecrolimus 1 %): Useful for steroid‑phobic patients or for maintenance therapy; they have no atrophogenic effect.
• Topical testosterone or estrogen creams: Occasionally prescribed for post‑menopausal women, though evidence is limited.

Systemic therapy (reserved for refractory disease)

• Oral prednisolone short courses.
• Hydroxychloroquine or methotrexate in patients with documented autoimmune overlap.

Surgical interventions

Surgery is not a cure and is only considered after inflammation is fully controlled.

• Fissure repair or skin grafting: For chronic, painful fissures that do not heal with medical therapy.
• Vulvar reconstruction: In severe cases with significant scarring, performed by a specialist in genital reconstructive surgery.
• All procedures carry a risk of worsening the disease if performed on active inflammation.

Adjunctive lifestyle measures

• Gentle cleansing with non‑ionic, fragrance‑free cleansers.
• Avoiding tight underwear, synthetic fabrics, and irritants.
• Using water‑based lubricants during sexual activity.

Living with Kraurosis Vulvae

Long‑term management focuses on symptom control, emotional wellbeing, and regular follow‑up.

Daily skin care

• Take lukewarm (not hot) showers; pat the area dry—do not rub.
• Apply a thin layer of prescribed ointment after cleaning, especially before bedtime.
• Use cotton underwear and change them after sweating or exercise.

Sexual health

• Communicate openly with partners; use plenty of hypoallergenic lubricant.
• If intercourse is painful, discuss with a gynecologist about possible dilator therapy.

Emotional support

• Consider counseling or support groups; chronic vulvar conditions are linked to anxiety and depression in up to 30 % of patients. WHO.
• Keep a symptom diary to track triggers and treatment response.

Follow‑up schedule

• Initial follow‑up 4–6 weeks after starting therapy to assess response.
• Thereafter, visits every 6–12 months, or sooner if new lesions appear.
• Annual vulvar examination by a specialist is advised because of the small but real risk of cancer.

Prevention

Because the exact cause is unknown, primary prevention is limited, but certain measures can reduce risk or delay onset.

• Maintain good vulvar hygiene without harsh soaps.
• Avoid chronic irritation – wear breathable cotton undergarments.
• Manage underlying autoimmune disease promptly.
• For post‑menopausal women, discuss the benefits of low‑dose vaginal estrogen with a clinician if there are no contraindications.

Complications

If left uncontrolled, kraurosis vulvae can lead to serious sequelae.

• Genital scarring and stenosis: May cause urinary retention or severe dyspareunia.
• Chronic fissures and ulceration: Can become infected, leading to cellulitis.
• Vulvar intraepithelial neoplasia (VIN) and squamous cell carcinoma: Cumulative lifetime risk of ~4–5 % in untreated patients; early detection dramatically improves outcomes. CDC.
• Psychosocial impact: Decreased quality of life, relationship strain, and mental health disorders.

When to Seek Emergency Care

---

**References**

1. Mayo Clinic. “Lichen sclerosus.” Updated 2024. https://www.mayoclinic.org
2. Centers for Disease Control and Prevention. “Vulvar Cancer Prevention.” 2023. https://www.cdc.gov
3. National Institutes of Health, National Library of Medicine. “Lichen sclerosus: Pathogenesis and Management.” 2022. https://www.ncbi.nlm.nih.gov
4. Cleveland Clinic. “Vulvar Lichen Sclerosus.” 2024. https://my.clevelandclinic.org
5. World Health Organization. “Mental health and chronic disease.” 2023. https://www.who.int

```